Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
about
Pegloticase for chronic goutThe tumor lysis syndromeGout--current diagnosis and treatmentThe emerging role of biotechnological drugs in the treatment of goutInduced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipientsReassessing serum urate targets in the management of refractory gout: can you go too low?Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice.2011 recommendations for the diagnosis and management of gout and hyperuricemia.An old disease with new insights: Update on diagnosis and treatment of gout.[The etiology and management of gout].New drugs approved in 2010New and improved strategies for the treatment of goutAdvances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.An update on the pathology and clinical management of gouty arthritis.Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APSInfluence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts.Latest evidence on gout management: what the clinician needs to knowDevelopment of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed MutagenesisHyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.Critical appraisal of the role of pegloticase in the management of gout.The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.Gout. Novel therapies for treatment of gout and hyperuricemia.Treating to target: a strategy to cure gout.Gout--what are the treatment options?Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trialsTophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout.New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.New advances in the treatment of gout: review of pegloticaseAllopurinol, uric acid, and oxidative stress in cardiorenal disease.Managing your patient with gout: a review of treatment options.Pegloticase: in treatment-refractory chronic gout.Pegloticase: a novel agent for treatment-refractory gout.Febuxostat treatment for gout: what the clinician needs to know.Gout and its comorbidities: implications for therapy.Evaluation and treatment of gout as a chronic disease.Current concepts in the treatment of gouty arthritis.PEGylated drugs in rheumatology--why develop them and do they work?
P2860
Q24236711-F43C8640-5867-4445-90C8-2E1DBD4ABD1FQ24605151-D6D7F658-A812-4F48-9FC4-EA5CDF619CF4Q24644156-CA4A089C-D4C5-47F8-90FC-75E332B9BD63Q26825459-965CA9DC-5579-4BEF-8518-9C3AB7042DEFQ33766720-236CFF9D-BC67-4390-94F4-D776C93F9658Q34061506-5D0206B3-B73E-4303-967C-C6E54C4387A3Q34069534-73269A35-F1CC-4848-A490-E4C1B83EF7E5Q34151625-C4CEEAED-3246-4DCE-B9D7-5E5C92310FEFQ34250995-A5C6EB59-82DC-4025-89AB-A9F5368C8A67Q34542091-7F7E0CC5-07A7-4D3F-AF39-17846CDB2B73Q34636225-588DB932-A6CF-4EE2-A26D-8932CFC9DA5CQ34753085-F73C9CB7-13D4-4418-B32E-FB0DFD944DB4Q35026692-CEBAD9EE-590A-4CA1-A6B3-5681F1E7BD46Q35026721-5D89B1E4-230F-415D-A7E0-43FB5792D3C8Q35643985-D0104116-4C79-40AF-B5E5-F3123A811B6DQ35671286-EBD593AF-AE7E-43E9-9D44-9EC1DF60412EQ35843950-E8E4469A-4916-4098-BB8C-7266145F3EFCQ36235198-FF2BAEA7-9265-4EAF-9EBA-9407EC22FF89Q36515484-F0F725DA-86E3-4B5A-89D7-435456C16883Q36939339-535D62FC-D077-4572-978B-1B37FE6A7E4DQ37127097-964DED73-9B2A-48EC-B6ED-77387F750BCAQ37301152-6311BD38-9D49-4F8F-AD7B-E45DD8019932Q37321292-BC8C0EB6-4831-4380-9724-2D06E1A12523Q37350841-DC3D0524-2FA4-476A-B9EB-9CB90653EF0FQ37485337-A542CE3B-4384-4AC5-A67B-8A0C43433115Q37492596-9D3CFD4A-5983-4A21-A5D7-38F2D057F39CQ37607659-4AC30C04-1F83-4D77-AD5E-AFFC0A4B26A8Q37690972-7E0C5410-D25F-4499-9008-916D201D36D3Q37702650-085302A1-FFAC-4643-AC32-8F30BEE469EEQ37738116-4E7FF1DA-311F-4DE5-83DE-B587B671A134Q37815379-A1C1DD43-A04E-4542-B70F-CEB8EC693E0CQ37872639-269FAAA3-4303-473A-99C4-E52731DBC89AQ37874889-DDF9B02F-D796-4A37-AAC6-6EDB4E7C84F1Q37950519-0C27B559-C58D-46F1-9571-2F698096133BQ37991129-EFDD6E3D-9887-483C-8D13-50F5BA6575BAQ38032563-ECF935F1-047A-43AB-8BD0-21D4AC898487Q38040777-0EB5D920-6A6D-4122-AB67-C48CCC30E927Q38056075-9D782395-F6C6-48AB-B277-F9B10F20987AQ38082745-C8044989-31C7-4F0B-933E-1BA9F9B18D73Q38130374-3A068243-D735-429E-9B3B-865D27D8FE26
P2860
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Reduction of plasma urate leve ...... f a phase II randomized study.
@en
Reduction of plasma urate levels following treatment with multiple doses of pegloticase
@nl
type
label
Reduction of plasma urate leve ...... f a phase II randomized study.
@en
Reduction of plasma urate levels following treatment with multiple doses of pegloticase
@nl
prefLabel
Reduction of plasma urate leve ...... f a phase II randomized study.
@en
Reduction of plasma urate levels following treatment with multiple doses of pegloticase
@nl
P2093
P356
P1476
Reduction of plasma urate leve ...... f a phase II randomized study.
@en
P2093
Allan N Maroli
Andre Barkhuizen
Herbert S B Baraf
John S Sundy
Larry W Moreland
Michael A Becker
Pegloticase Phase 2 Study Investigators
Royce W Waltrip
William Huang
Zeb Horowitz
P304
P356
10.1002/ART.23810
P577
2008-09-01T00:00:00Z